Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
By utilizing whole-genome sequencing, DNA copy number analysis and RNA-seq, researchers discovered recurrent somatic point mutations and genes that were targeted by focal somatic deletions in diffuse large B-cell lymphoma (DLBCL).
Using nanofluidic proteomic immunoassay researchers demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2.
This study on Acute myeloid leukemia (AML) indicates that transcriptome sequencing is useful for biomarker discovery, as exemplified by the identification of ITGA5 -E2/3 splice variant as potential novel adverse prognostic marker for low-risk AML.
These results establish that the CRISPR system can be used as a modular and flexible DNA-binding platform for the recruitment of proteins to a target DNA sequence, revealing the potential of CRISPRi as a general tool for the precise regulation of gene expression in eukaryotic cells.
Researchers discuss an integrated methodology based on pooled shRNA screening in mammalian cells for genome-wide identification of genes with relevant phenotypes and systematic mapping of all genetic interactions.
Researchers introduce a computational approach to identify recurrent regions of the genome in noisy data known as cores of recurrent events (CORE), and apply it to comparative genomic hybridization data from a large set of breast cancer samples.
Researchers identiy tens of thousands of putative lincRNAs that are strongly enriched for trait-associated SNPs suggesting a new mechanism by which intergenic trait-associated regions may function.
The emergence and convergence of cancer genomics, targeted therapies, and network oncology have significantly expanded the landscape of protein-protein interaction (PPI) networks.
Researchers explored the effects of FOXO1 mutations in DLBCL patient samples and DLBCL-derived cell lines and suggested FOXO1 mutation as a novel prognostic factor in DLBCL pathogenesis.